कृपया अन्य खोज का प्रयास करें
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with insulin for late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson’s disease; and Fructokinase Inhibitor for Metabolic disease. The company was incorporated in 2011 and is based in Beijing, China.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Robert Taylor Nelsen | 60 | 2010 | Non-Executive Chairman |
Li Chen | 59 | 2010 | Founder, CEO & Executive Director |
Yiu Leung Cheung | 64 | 2023 | Independent Non-Executive Director |
Yiu Wa Tsui | 74 | 2018 | Independent Non-Executive Director |
James S. MacDonald | - | - | Member of Scientific Advisory Board |
Chien Cheng Lin | 53 | 2017 | Executive VP, Chief Strategy Officer & Executive Director |
Bennett M. Shapiro | 84 | - | Member of Scientific Advisory Board |
Catherine D. Strader | 69 | - | Member of Scientific Advisory Board |
William Robert Keller | 76 | 2018 | Independent Non-executive Director |
Fangxin Li | 32 | 2023 | Non-Executive Director |
Yi Zhang | 49 | 2018 | Senior VP of Pharma Development, Chief Medical Officer – China and Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है